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In vitro studies demonstrate that the increased alloreactive T cell response to dendritic cells (DC) that are treated with
either live or inactivated influenza virus A/PR/8/34 is due to viral neuraminidase (NA) activity. Since virus-specific cytotoxic
T lymphocytes (CTL) play an important role in immunity to heterologous influenza strains, we compared the activation of
CD81 T cells by untreated and NA-treated DC. Increased CTL activity was induced by NA-treated DC both in vitro and in vivo.
Since the generation of CTL in response to influenza virus infection does not require prior “activation” of DC by CD41 T cells
(as is the case for many antigens), we asked whether NA activity contributed to this unconditional CD81 T cell response. This
was not the case. Future studies will determine the factors that are responsible for the CD41 T-cell-independent influenza
virus-specific CTL response. © 2001 Academic Press
1Key Words: influenza virus; neuraminidase; dendritic cells; cytotoxic T lymphocytes; CD8 T cells; sialic acid; vaccines;
ICAM-1.
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CINTRODUCTION
The generation of cytotoxic T lymphocytes (CTL) plays
a significant role in recovery from infection by influenza
virus (Doherty et al., 1992). The initiation of this response
depends on the CD81 T cell’s interaction with MHC class
I peptide complex, costimulatory molecules, and ad-
hesins on an activated dendritic cell (DC) (Banchereau et
al., 2000; Schuurhuis et al., 2000). CD41 T helper cells
are usually required to activate DC (Ridge et al., 1998;
Bennett et al., 1998; Schoenberger et al., 1998). However,
infection of DC with influenza virus results in an activated
phenotype (Cella et al., 1999; Larsson et al., 2000). This
may explain why the generation of influenza virus-spe-
cific CTL does not require CD41 T cell help. This CD41 T
cell independence has been demonstrated in vivo: mice
that lack either CD41 T cells (Allan et al., 1990) or MHC
class II (Tripp et al., 1995) generate a substantial number
of CTL during the primary acute response to influenza
virus.
Our in vitro studies demonstrate that the increased
alloreactive T cell proliferation (Oh and Eichelberger,
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4031999; Oh et al., 2000) and IL-2 and IFN-g secretion (Oh
and Eichelberger, 2000) in response to DC that are
treated with either live or inactivated influenza virus
A/PR/8/34 (PR8) are due to the viral neuraminidase (NA)
activity. The effector cells used in these assays were
bulk populations of T cells. Since the predominant sub-
set in such a population is CD41, it was important to
establish that NA treatment of DC also enhanced CTL
responses. We therefore examined the effect of desialy-
lation on the generation of antigen-specific CD81 T cells
nd asked whether NA accounted for the CD41 T cell
independence of the influenza virus-specific CD81 T cell
response.
RESULTS
Treatment of DC with viral NA results in enhanced
proliferation and cytotoxicity of alloreactive CD81 T
cell responses in vitro
We isolated CD41 and CD81 T cells from the spleens
of BALB/c mice and mixed them with DC that had been
cultured from the bone marrow of C57BL/6 mice. As
shown in Fig. 1, proliferation of both allogeneic CD41 and
D81 T cells was increased by stimulation with DC that
had been infected with PR8 or treated with NA. In con-
trast, infection with NWS-Mvi, a NA-deficient virus, or
infection with PR8 in the presence of zanamivir, a NA-
specific inhibitor, did not result in an increase in prolif-
eration. Correlating with proliferation, increased
amounts of IL-2 and IFN-g were detected in the super-
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404 OH, BELZ, AND EICHELBERGERnatants of both allogeneic CD41 and CD81 T cell cul-
tures that had been stimulated by NA-treated DC (results
not shown).
To determine whether desialylation of DC altered the
accessibility of molecules known to contribute to T cell
activation, untreated, NA-treated, and PR8-infected DC,
as well as DC that were infected with PR8 in the pres-
ence of zanamivir, were stained with antibodies to
ICAM-1, B7-1, B7-2, and CD40. Immunostaining with anti-
CD43, which is dependent on sialic acid for binding,
demonstrated that the DC were indeed hyposialylated
after NA treatment and PR8 infection and that infection in
the presence of zanamivir inhibits NA activity (Fig. 2).
Increased CD103, CD11a, and CD62L immunofluores-
cence was observed after PR8 infection. For example,
the mean fluorescence intensity (mfi) for CD103 before
FIG. 1. Proliferation of allogeneic (A) CD41 and (B) CD81 T cells to
untreated, PR8-infected, Mvi-infected, and NA-treated DC. DC were
prepared by in vitro culture of bone marrow cells from C57BL/6 (H-2b)
mice and were either left untreated or infected with 2.5 m.o.i. of PR8 or
Mvi, a NA-deficient virus. Zanamivir (1 mM), a viral NA inhibitor, was
added to some DC during the PR8 infection. Some DC were treated
with 5 mU/ml viral NA for 2 h at 37°C. After infection or NA treatment,
DC were irradiated and washed and 5 3 103 DC were mixed with 5 3
105 T cells (H-2d) in quadruplicate wells of a round-bottom 96-well plate.
ultures were incubated at 37°C and 1 mCi [3H]thymidine was added
nto each well on day 3. Incorporation was determined after a further
8 h incubation. The data shown represent the mean cpm 6 SE for four
epeat experiments. Proliferation that is marked with an asterisk is
tatistically different (P , 0.05) from proliferation without PR8 infec-
ion, as determined by the Wilcoxon rank test.infection was 5.2 and after infection 10.4. This reflects a
shift in the population of cells that is easily observed by oan increase in the percentage of positively stained cells.
Increased immunofluorescence with antibodies to
CD103, CD62L, and CD11a was not NA-dependent: the
increase was not observed when cells were treated with
NA and was still observed when cells were infected in
the presence of NA inhibitor (Fig. 2).
The increased immunofluorescence with antibodies to
CD40, ICAM-1, B7-1, B7-2, and MHC class II was, how-
ever, NA-dependent. Increased immunofluorescence
was observed when DC were infected with PR8 in the
absence, but not the presence, of a NA inhibitor. Similar
increases were observed for DC treated with purified NA
(Fig. 2). These changes, although small (for example, the
mfi for CD40 for untreated CD was 6.9 and on PR8-
infected DC was 8.2), were consistently observed in
repeat experiments. The percentage change in mean
fluorescence intensity for each cell surface marker after
infection with NWS-Mvi was similar to the change after
infection with PR8 in the presence of zanamivir (data not
shown), further demonstrating the dependence on viral
NA for these changes.
Since each of these molecules contributes to the ac-
tivation of T cells, proliferation assays were performed in
the presence of blocking antibodies to determine
whether any of the molecules with increased accessibil-
ity contributes to the enhanced proliferation of CD81 and
D41 T cells. The proliferation of each subset of T cells
in response to NA-treated DC was reduced in the pres-
ence of antibodies specific for ICAM-1, CD2, B7-1, and
B7-2, but not CD62L (Fig. 3). The amount of inhibition was
FIG. 2. Immunofluorescence of DC after treatment with viral NA or
infection with PR8 in the absence or presence of zanamivir, compared
with immunofluorescence of untreated DC. DC were cultured in the
presence of GM-CSF for 7 days, washed, and then treated with purified
viral NA (5 mU/ml) for 2 h at 37°C, infected with 2.5 m.o.i. PR8 for 4 h
at 37°C in the presence or absence 1 mM zanamivir, of left untreated.
Cells were incubated with FITC-conjugated antibodies with specificity
for each of the cell surface molecules indicated or isotype controls (not
shown). The average percentage differences in mean fluorescence
intensity (mfi) obtained in at least three separate experiments are
shown [i.e., 100 3 (mfi of treated DC 2 mfi of untreated DC)/mfi of
untreated DC]. The SD was less than 20% of the difference in mfi.
Immunofluorescence of infected cells with anti-CD103, CD11a, and
CD62L was significantly different (determined by t test) from immuno-
fluorescence with anti-CD40, B7-1, B7-2, ICAM-1, IAb, and Kb. Stainingbwith anti-CD43, CD40, B7-1, B7-2, ICAM-1, and IA was significantly less
n cells that had been treated with zanamivir.
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405NEURAMINIDASE AND CD81 T CELL RESPONSESgreatest in the presence of antibodies to ICAM-1, with
almost 50 and 60% of the response of CD81 and CD41 T
cells inhibited, respectively (Fig. 3). Proliferation to un-
treated DC was not reduced to a similar extent.
To determine whether in vitro stimulation of T cells
with NA-treated DC resulted in an increase in allospe-
cific cytotoxicity, H-2b DC that were untreated, or that had
een infected with PR8 or treated with viral NA, were
sed to stimulate mixtures of CD41 and CD81 H-2d T
cells or CD81 T cells alone. Five days after stimulation, T
ells were counted and added to 51Cr-labeled MC57G
ells at various effector:target (E:T) ratios. Both unsepa-
1
FIG. 3. Proliferation of (A) CD41 and (B) CD81 T cells to allogeneic
A-treated or untreated DC in the presence of antibodies to block
pecific cell surface molecules. In vitro- cultured DC (H-2b) were incu-
bated for 2 h at 37°C with, or without, the addition of 5 mU/ml influenza
virus NA. DC were then irradiated and washed, and 5 3 103 DC were
ixed with 5 3 105 CD41 or CD81 T cells that had been purified from
the spleens of H-2d mice. Each antibody was added to quadruplicate
ultures in round-bottom 96-well plates at 2 mg/ml. On day 3, 1 mCi
3H]thymidine was added to each well and incorporation determined
after a further 18 h incubation. Each column shows the mean of
quadruplicate cpm 6 SD. The percentage of the response to either
ntreated or NA-treated DC in the absence of any blocking antibodies
s given beneath the relevant column. The data shown are the averages
nd SD for one of three experiments. In each experiment the reduction
n proliferation to NA-treated DC was statistically significant in the
resence of antibodies to B7-1, B7-2, ICAM-1, and CD2 (P , 0.01, t
est), with the greatest decrease observed with anti-ICAM-1.ated T cells and purified CD8 T cells that had been
stimulated by NA-treated or influenza virus-infected DChad greater cytolytic activity than T cells stimulated by
untreated DC (Table 1).
Ex vivo treatment of DC with viral NA increases the in
vivo peptide-specific CD81 T cell response
To determine whether desialylation of antigen-pre-
senting cells can enhance the in vivo peptide-specific
CD81 T cell response, BALB/c mice were immunized
ith peptide-loaded DC that were either NA treated or
ntreated. DC were loaded with either both MHC class I
d (HA518–528) (Morgan et al., 1996) and class II (HA111–119)-
restricted (Kirberg et al., 1994) peptides from influenza
hemagglutinin (HA) or only the MHC class I-restricted
peptide. Following incubation with peptide, DC were
divided into two groups: untreated and NA treated. Ex-
cept for the addition of NA, each of these groups was
handled in the same way, i.e., incubated for 2 h at 37°C,
irradiated, washed, and counted. Three weeks after in-
travenous immunization of BALB/c mice with 5 3 105 DC,
plenocytes were restimulated with the same peptide(s)
sed for immunization, and the cytotoxicity of these cells
as measured by lysis of 51Cr-labeled HA518–528-pulsed
815 cells. Splenocytes from mice immunized with both
HC class I- and class II-restricted peptide-loaded DC
ad greater specific cytotoxicity than splenocytes from
ice immunized with only MHC class I-restricted pep-
ide-loaded DC (Fig. 4), suggesting a contribution of
D41 T cells to the activation and expansion of antigen-
pecific CTL. This difference, however, was not observed
n cultures from the mice immunized with NA-treated DC.
n fact, in the absence of immunization with MHC class
I-restricted peptide, CTL responses to NA-treated DC
ere greater than even those from mice immunized with
ntreated DC that had both peptides loaded.
To determine whether NA alters the cytolytic capacity
f each cell, or whether our results reflect an increased
TABLE 1
Cytotoxicity of Alloreactive T Cells Stimulated by DC That Were
Treated with Viral NA or Infected with PR8
Responding T cellsa
% specific cytotoxicityb of alloreactive T
cells after stimulation with DC treated with
None NA PR8 (2.5 m.o.i.)
CD81 18 6 1.1 42 6 1.4 39 6 1.5
CD41 1 CD81 28 6 1.4 39 6 1.3 38 6 1.7
a 5 3 105 CD81 T cells or a mixture of CD41 and CD81 T cells from
he spleens of H-2d mice were stimulated with 5 3 103 H-2b DC that had
been left untreated (none), treated with 5 mU/ml viral NA, or infected
with 2.5 m.o.i. PR8. Cells were incubated at 37°C in round-bottom
96-well plates for 5 days before the 51Cr release assay was performed.
b 51Cr-labeled MC57G cells were used as targets at various E:T ratios.
Data shown are for E:T of 10:1 and represent means 6 SD of triplicate
cultures. Similar results were observed in three repeat experiments.
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406 OH, BELZ, AND EICHELBERGERnumber of activated antigen-specific CD81 T cells, the
requency of IFN-g-producing cells in spleens of mice
that were immunized with untreated and NA-treated DC
was determined. Three weeks after immunization,
spleens from five or six mice/group were restimulated in
vitro with the peptide(s) that had been used to prime the
response. The total number of splenocytes from mice
immunized with NA-treated DC was slightly higher than
that of splenocytes from mice immunized with untreated
DC (for mice immunized with untreated vs NA-treated
DC, the number of splenocytes without peptide immuni-
zation was 108 vs 114 3 106, with HA518–528 only 117 vs
122 3 106, and with both HA518–528 and HA111–119 121 vs
24 3 106). These differences were not statistically sig-
ificant. The number of cells in each lymphocyte subset
as calculated from the percentage of cells that stained
ositive for B220, CD4, and CD8. Splenocytes from mice
mmunized with both MHC class I- and II-restricted pep-
ides had greater numbers of CD41 T cells than cultures
from mice immunized with DC in the absence of antigen
or with MHC class I-restricted peptide only. However, the
difference between the number of CD41 T cells from
mice that had been immunized with untreated DC and
the number of CD41 T cells from mice that had been
immunized with NA-treated DC was not significant. Mice
immunized with both HA518–528 and HA111–119 had 32 vs
34 3 106 CD41 T cells when DC were untreated or NA
FIG. 4. The peptide-specific CD81 T cell response that is stimulated
n vivo is enhanced by immunization with NA-treated DC. DC (H-2d)
were incubated in 2 ml complete medium containing 10 mg/ml MHC
class I- or both class I- and class II-restricted peptides of influenza
virus HA for 1 h at 37°C. After being washed, peptide-loaded DC were
resuspended in complete medium, incubated in the presence or ab-
sence of viral NA as described for the previous figures, and irradiated.
Groups of five or six BALB/c mice were immunized by intravenous
injection of 5 3 105 DC/mouse. After 3 weeks, splenocytes from
ndividual mice were restimulated by culture for 5 days at 37°C in 10
mg/ml of the immunizing peptides. The cytolytic activity of each culture
to 51Cr-labeled, class I peptide-loaded P815 was measured in triplicate
ells at various E:T ratios. Results are shown at E:T of 30:1 and
epresent the mean % specific 51Cr release for each of the mice in a
roup.treated, respectively. In the absence of the MHC class
II-restricted peptide, the number of CD41 T cells/spleen
cranged between 26 and 29 3 106. However, there was a
ignificant difference in the number of CD81 T cells
nduced by untreated and NA-treated DC (P , 0.05, Fig.
5A). The difference was antigen-specific and was not as
evident when immunization included MHC class II-re-
stricted peptide since this resulted in a greater number
of CD81 T cells in the culture, even when DC had not
been treated with NA (Fig. 5A).
A significantly greater number of IFN-g-producing
CD81 T cells was present in the spleens of mice immu-
nized with NA-treated HA518–528-loaded DC than with un-
treated HA518–528-loaded DC (P 5 0.05, Fig. 5B). The
ifference was more clearly evident when the culture
upernatants of spleen cells were analyzed for IFN-g
production after restimulation. Lymphocytes from mice
immunized with NA-treated DC pulsed with HA518–528 only
ecreted significantly more IFN-g than lymphocytes from
ice immunized with peptide-loaded DC that had not
een treated with NA (Fig. 5C). Similar differences were
bserved when the numbers of peptide-specific CD81 T
ells and IFN-g CD81 T cells that expand following im-
unization were calculated by subtracting the number of
D81 T cells present in mice that were immunized with
C that were not loaded with peptide. The mean num-
ers of antigen-specific CD81 T cells following immuni-
zation with HA518–528-loaded untreated and NA-treated DC
ere 4.0 3 105 and 34.8 3 105, respectively. Following
mmunization with both HA518–528 and HA111–119 the num-
bers of peptide-specific CD81 T cells were 36.0 3 105
and 49.8 3 105, respectively. The mean numbers of
antigen-specific IFN-g1 CD81 T cells following immuni-
ation with HA518–528-loaded untreated and NA-treated DC
ere 0.12 3 105 and 2.67 3 105, respectively, and with
both HA518–528 and HA111–119 were 2.1 3 10
5 and 3.67 3 105,
espectively. Lymphocytes from mice immunized with
A-treated DC pulsed with both HA518–528 and HA111–119
secreted significantly more IFN-g than lymphocytes from
ice immunized with peptide-loaded DC that had not
een treated with NA (Fig. 5C). The increased number of
esponding CD41 T cells probably contributes to this
ifference since these cultures were restimulated in the
resence of both MHC class I and class II-restricted
eptides. In contrast, the amount of IL-4 in culture su-
ernatants was significantly less in cultures from mice
mmunized with NA-treated DC (Fig. 5D).
D81 T cell responses to influenza virus are retained
n CD4-deficient mice that are infected with a NA-
eficient virus
To address the contribution of NA to the generation of
D41 T-cell-independent responses in vivo, we exam-
ined the CD81 T cell response to NWS-Mvi, a NA-defi-
1ient virus, in the presence and absence of CD4 T cells.
This virus was derived by selection of NWS/G70c (H1N9)
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407NEURAMINIDASE AND CD81 T CELL RESPONSESvariants in the presence of exogenously provided bacte-
rial NA (Liu and Air, 1993). When mice were depleted of
CD41 T cells by antibody (GK1.5) treatment, no differ-
ences in CD81 T cell responses were observed (results
not shown). Since this lack of difference could have been
the result of incomplete depletion, immunologically intact
and CD4-deficient (CD4 (2/2)) C57BL/6 mice were in-
ected intranasally with either the parental virus, NWS/
70c, or NWS-Mvi. Ten days after infection, influenza
irus-specific CD81 T cells were identified by staining
with phycoerythrin (PE)-labeled H-2Db tetramers that
were loaded with peptides from polymerase 2 (PA224–233)
nd nucleoprotein (NP366–374) (Belz et al., 2000). Table 2
shows the number and percentage of CD81 T cells in the
bronchoalveolar lavage (BAL) and draining mediastinal
b
FIG. 5. Analysis of the (A) number of CD81 T cells, (B) number of IFN
D) IL-4 in splenocyte culture supernatants from mice immunized with gr
oaded with MHC class I-restricted peptide HA518–528 (class I) or both H
added peptide (none). BALB/c mice were immunized with 5 3 105 DC
ontaining 10 mg/ml of the peptide(s) used for immunization and then
ytometry to determine the number of IFN-g-producing CD81 T cells. IF
restimulation of 1 3 106 spleen cells with the immunizing peptides, re
s given. Statistically different (P # 0.05) results from mice immunized w
s determined by the Wilcoxon rank test.lymph nodes (MLN) that have specificity for D -restricted
A224–233 (D
bPA224) and for D
b-restricted NP366–374 (D
bNP366).lthough the number of DbPA224 and D
bNP366-specific
D81 T cell was less than the number of antigen-specific
CD81 T cells in NWS/G70c-infected mice, Table 2 clearly
hows that influenza virus-specific CD81 T cells are
resent in the BAL and MLN of both intact and CD4(2/2)
ice after infection with NWS-Mvi. This shows that viral
A is not necessary to generate CD81 T cell responses
in the absence of CD41 T cell help.
DISCUSSION
We have examined the induction of CD81 T cell re-
sponses by untreated and NA-treated DC in vitro and in
vivo. When either CD41 or CD81 T cells were stimulated
by allogeneic NA-treated DC in vitro, proliferation (Fig. 1)
ucing CD81 T cells, (C) IFN-g in splenocyte culture supernatants, and
f untreated (open bars) or NA-treated (filled bars) DC. The DC had been
and HA111–119 (class I and II) or were not incubated in the presence of
. After 3 weeks, splenocytes were resuspended in complete medium
d at 37°C for 24 h. Cells were immunostained and analyzed by flow
d IL-4 were measured by ELISA in cell supernatants 2 and 3 days after
ely. The mean cell number or quantity of cytokine 6 SE (n 5 5 mice)
-treated DC compared with untreated DC are marked with an asterisk,-g-prod
oups o
A518–528
/mouse
culture
N-g an
spectivand production of IL-2 and IFN-g (results not shown)
were increased. Cytotoxicity of cultures containing allo-
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408 OH, BELZ, AND EICHELBERGERreactive CD81 T cells increased in a similar manner
Table 1).
Our data do not show whether these increased re-
ponses reflect the activation of a larger number of
recursor T cells or increased expansion of activated
lones. The change in conformation of MHC class I and
I molecules after desialylation may, for example, result
n the activation of a larger number of allogeneic T cells.
owever, changes in the accessibility of key cell surface
olecules may result in the activation of T cells with
reater proliferative potential. Indeed, cells treated with
A had increased fluorescence when stained with anti-
odies to CD40, ICAM-1, B7-1, and B7-2. Each of these
olecules contributed to the T cell response to NA-
reated allogeneic DC. However, proliferation to NA-
reated, but not untreated, DC was reduced the most in
he presence of anti-ICAM-1 (Fig. 3). A similar depen-
ence on ICAM-1 has been demonstrated for T cell
esponses to NA-treated B cells (Bagriacik and Miller,
999). This is not surprising since ICAM-1 is a prominent
ell surface antigen, extending approximately 40 nm
rom the plasma membrane, and is therefore one of the
irst antigens to facilitate stable contact between anti-
en-presenting cell and T cell (Dustin and Shaw, 1999).
uture studies will examine how sialic acid influences
he interaction between ICAM-1 and its ligand, LFA-1.
The enzymatic activity of NA is essential for release of
ewly formed influenza virions form the infected host
ell. Inhibition of NA with neutralizing antibodies or in-
T
Influenza Virus-Specific CD81 T Cell Responses
Source of cellsa Virus strain Specificity W
BAL NWS/G70c DbPA224
DbNP366
NWS-Mvi DbPA224
DbNP366
MLN NWS/G70c DbPA224 4
DbNP366 2
NWS-Mvi DbPA224 1
DbNP366 1
a Groups of wild-type and CD4 (2/2) C57BL/6 mice were infected i
AL of each group were pooled and MLN were individually harvested
b Cells were stained with FITC-labeled anti-CD8 and PE-conjugated D
percentage of CD81 T cells with antigen specificity is the percentage o
c The number of CD81 T cells with antigen specificity was calculated
number of cells in BAL and MLN preparations. BAL was pooled from th
of total lymphocytes was divided by the number of mice in the group).
rom the MLN are given for an experiment that included three to five m
AL samples from NWS/G70c and NWS-Mvi-infected wild-type and CD
DbNP366–PE gave similar results.ibitors therefore limits the spread of infection. Compar-
son of virus-specific CD81 T cell responses in the pres-
a
Tence or absence of such inhibition, or in response to
intact versus NA-deficient viruses, is consequently likely
to reflect differences in replication rather than the con-
tribution of NA to T cell proliferation. To determine
whether viral NA can enhance CD81 T cell responses in
ivo, we therefore compared the responses to a MHC
lass I-restricted peptide, HA518–528, presented by DC that
ad, or had not, been treated with NA. Figure 4 shows
hat CD81 T cell cultures from the spleens of mice that
ere immunized with desialylated peptide-loaded DC
ave greater cytolytic activity than cultures from mice
hat were immunized with untreated DC. These results
re the first to show that a CD81 T cell response can be
nhanced by ex vivo treatment of DC with NA. Antigen-
ransfected DC have been used in clinical trials to stim-
late immune responses to tumors, and responses to
uch vaccines have been enhanced by cotransfection
ith costimulatory molecules or cytokines. Our results
herefore provide an alternate method to enhance the
mmunogenicity of DC vaccines without presenting ad-
itional genes and/or cytokines to the recipient.
In our experiments, CTL responses to DC pulsed with
HC class I-restricted peptide only were poorly gener-
ted. This suggests that the CTL response to HA518–528 is
CD41 T cell dependent. However, the presence of some
CD41 T cells generated in response to peptides gener-
ted from serum or other components during the ex vivo
ulture of DC may support the enhanced CTL response
ince they too will proliferate and secrete IL-2 in greater
/G70c (H1N9) and NWS-Mvi (H1, NA Deficient)
tageb of CD81 T cells
h Ag-specificity in
Numberc of Ag-specific CD81 T
cells (3103) in
CD4 (2/2) Wild type CD4 (2/2)
22.9 87.0 133.0
7.2 41.9 42.0
29.4 7.3 8.5
30.8 7.6 8.9
4.5 6 1.6 25.3 6 12.5 71.3 6 23.3
2.5 6 1.6 14.7 6 7.7 38.1 6 11.2
2.6 6 1.7 9.0 6 2.3 5.2 6 3.9
1.2 6 0.8 9.0 6 3.7 6.6 6 8.0
ally with 30 ml NWS/G70c or NWS-Mvi. Ten days later, cells from the
nd DbNP366 tetramers as described under Materials and Methods. The
T cells that stained positive with either DbPA224 or D
bNP366 tetramers.
ltiplying the percentage of total cells that were tetramer1 with the total
ive mice and the number of cells is shown per mouse (i.e., the number
erage 6 SD percentage and number of antigen-specific CD81 T cells
r group. A separate experiment in which cells from pooled MLN and
) C57BL/6 mice were stained with anti-CD8–FITC and DbPA224–PE orABLE 2
to NWS
Percen
wit
ild type
31.0
14.9
47.3
49.1
.5 6 0.8
.7 6 0.6
.7 6 0.4
.7 6 0.4
ntranas
.
bPA224 a
f CD81
by mu
ree to f
The av
ice pemounts when generated in response to NA-treated DC.
herefore, the enhanced CTL response after NA treat-
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409NEURAMINIDASE AND CD81 T CELL RESPONSESment of DC (NA-treated DC loaded with HA518–528 stimu-
lated CD81 T cell responses to the same degree as
untreated DC loaded with both HA518–528 and HA111–119)
does not provide conclusive evidence that desialylation
of DC can substitute for CD41 T cell help. To determine
whether this is indeed possible, and is the reason for the
CD41 T-cell-independent influenza virus-specific CTL re-
sponse, we examined the CTL response generated to a
NA-deficient influenza virus, NWS-Mvi, in mice that do
not have CD41 T cells.
The majority of the influenza A virus-specific CD81 T
cell responses in C57BL/6 mice are generated with
specificity to DbPA224 and D
bNP366. The D
bPA224-specific
response is prominent in the primary immune response,
but the DbNP366-specific CD8
1 NP-specific response is
expanded in the secondary response (Belz et al., 2000).
Like responses to X-31 and PR8, DbPA224-specific CD8
1 T
ells were more prominent than DbNP366-specific CD8
1 T
ells in the BAL after NWS/G70c infection. In contrast,
bPA224- and D
bNP366-specific CD8
1 T cells were induced
with approximately equivalent frequency in mice infected
with NWS-Mvi (Table 2). This may result from differences
in replication of these strains since in the absence of NA,
infection by NWS-Mvi is limited (results not shown). It is
interesting to note that while the specificity of almost
100% of the CD81 T cells in the BAL are accounted for in
ild-type mice infected with NWS-Mvi, the DbPA224- and
DbNP366-specific CD8
1 T cells comprise approximately
60% of the CD81 T cell population in CD4 (2/2) mice.
This may reflect the presence of CD81 T cells that have
imited expansion in the presence of CD41 T cells or
ctivation of a greater repertoire of CD81 T cells due to
the extended duration of viral replication in CD4-deficient
mice (Allan et al., 1990). From the latter explanation, one
would expect the number of antigen-specific CD81 T
ells in infected CD4 (2/2) mice to be greater than the
umber of CD81 T cells in wild-type mice. This was
bserved for mice infected with NWS/G70c but not with
WS-Mvi. Future studies will determine whether this
as due to the limited replication of this NA-deficient
irus or whether the absence of NA activity resulted in
estricted expansion of these cells.
The BAL of both immunologically intact and CD4
2/2) C57BL/6 mice had a substantial proportion of
irus-specific CD81 T cells following infection with NWS-
vi. Viral NA is therefore not responsible for the CD41-
ndependent CTL response during influenza virus infec-
ion. A number of factors may contribute to the influenza
irus-specific CD41-independent CTL response. Charac-
teristics of activated DC that are upregulated during
influenza virus infection include increased expression of
cell surface molecules B7-2 and CD40 (Cella et al., 1999)
and cytokines IFN-a (Cella et al., 1999; Bender et al.,
1998), IL-1b (Pirhonen et al., 1999), and IL-12 (Oh and
Eichelberger, 2000). Our results show that NA contrib-
utes to the apparent increase in expression of B7-2 andCD40 by increasing their accessibility. It has been sug-
gested that some factors with increased expression in
influenza virus-infected DC are induced by double-
stranded (ds) RNA and it is assumed that this would
occur via the activation of PKR (Cella et al., 1999), a
kinase that is activated by binding of dsRNA (Wu and
Kaufman, 1996). However, in the cell types studied to
date, influenza virus uses at least two mechanisms to
overcome the activation of PKR: the viral NS1 molecule
itself binds to dsRNA and blocks the activation of PKR
(Lu et al., 1995) and infection activates the expression of
a 58-kDa protein that inhibits the activity of phosphory-
lated PKR (Melville et al., 1999; Tan and Katze, 1998). The
mechanism by which influenza virus activates DC may
therefore be different from the activation of DC by
dsRNA.
Identification of the mechanism that explains how in-
fluenza virus activates DC may lead to the design of
novel adjuvants for vaccines that are aimed at inducing
CTL responses or therapies that enhance immunity in
individuals with low numbers of CD41 T cells. Although
viral neuraminidase does not facilitate the CD41-inde-
pendent CTL response during influenza virus infection,
NA treatment of dendritic cells does facilitate expansion
of antigen-specific T cells. Desialylation may therefore
be a useful strategy to enhance the immunogenicity of
vaccines.
MATERIALS AND METHODS
Mice and cells
Five- to six-week-old female C57BL/6 (H-2b), BALB/c
H-2d), and CD4 (2/2) mice were purchased from The
ackson Laboratory (Bar Harbor, ME) and housed at
ohns Hopkins University. They were used at 6 to 10
eeks of age as approved by the Animal Care and Use
ommittee, Johns Hopkins School of Public Health.
DC were prepared by culture of bone marrow from
57BL/6 or BALB/c mice as previously described (Oh et
l., 2000). The cells were identified as DC by microscopic
xamination and immunostaining with antibodies to
D11c, B7-2, and MHC class II.
T cells from BALB/c spleens were prepared as previ-
usly described (Oh et al., 2000). CD81 T cells or CD41
T cells were separated by using rat anti-mouse CD8
(53-6.7) or rat anti-mouse CD4 (GK1.5) before incubation
with magnetic beads (Dynal, Norway). The purity of T
cells was greater than 95% as tested by flow cytometric
analysis.
Infection and NA treatment of DC
Stocks of PR8, NWS/G70c, and NWS-Mvi were pre-
pared and titrated on MDCK monolayers as previously
described (Oh and Eichelberger, 1999; Liu and Air, 1993).
Briefly, allantoic fluid containing PR8 virus and tissue
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410 OH, BELZ, AND EICHELBERGERculture supernatant containing NWS/G70c or a NA-defi-
cient NWS-Mvi virus were stored at 280°C. Virus titers
were determined by infection of MDCK cells. Ten-fold
dilutions of virus were made in serum-free DMEM (Life
Technologies, Gaithersburg, MD) and 100 ml of each
irus dilution was added to quadruplicate wells contain-
ng a monolayer of MDCK cells in a 96-well plate. After
h incubation at 37°C, 100 ml of DMEM supplemented
ith 3% BSA and 5 mg/ml trypsin was added to the wells.
For NWS-Mvi, the final culture medium also contained 1
mU/ml of Vibrio cholerae NA (Boehringer Mannheim).
fter 3 days incubation at 37°C, 25 ml of the supernatant
from each well was transferred into a round bottom
96-well plate. PBS (25 ml) and 0.5% chicken red blood
cells (50 ml) were added and hemagglutination was ob-
erved after 30 min at room temperature. The inverse of
he dilution at which 50% of the wells showed hemag-
lutination was recorded as the tissue culture infectious
ose (TCID50). The titer of each of the virus stocks was
09 TCID50/ml.
To infect DC, virus was added to tubes containing 1 3
106 cells at m.o.i. of 2.5 in 2 ml PBS. After 1 h incubation
t 37°C, 10 ml of RPMI containing 10% FCS and antibi-
tics (complete medium) was added, and the cells were
ncubated for 3 h at 37°C.
Purified viral NA (subtype N8) was kindly provided by
r. Graeme Laver (John Curtin School of Medical Re-
earch, Canberra, Australia). Viral NA activity was deter-
ined by using fluorescent substrate as previously de-
cribed (Oh and Eichelberger, 1999). To treat cells with
iral NA, 1 3 106 DC were incubated for 2 h in complete
edium containing 5 mU/ml NA at 37°C.
Both virus-infected and NA-treated DC were washed
everal times with complete medium, irradiated, and
ounted before they were added to T cell assays or used
o immunize mice. Control DC were treated in the same
ay, except that virus or NA was not added. In some
xperiments, zanamivir (von Itzstein et al., 1993), a virus-
pecific NA inhibitor, kindly provided by Glaxo-Wellcome,
as included during PR8 infection or NA treatment at 1
M.
mmunization with DC and infection with influenza
irus
DC were incubated at 107/ml for 1 h in PBS containing
0 mg/ml peptide, washed, and then divided into two
ubes, each containing cells at 106/ml. Viral NA was
added to one set of tubes for 2 h at 37°C. DC were
washed, irradiated, and counted. BALB/c mice were im-
munized by intravenous injection of 5–6 3 105 DC/
ouse. After 3 weeks, spleen cells from each mouse
ere restimulated with the same peptide(s) (10 mg/ml)
sed for immunization. Mice were infected intranasally
ith 30 ml NWS/G70c (1/40 dilution of stock) or NWS-Mvi(1/10 dilution of stock) while under sedation with Avertin
(2,2,2-tribromoethanol).
Immunostaining of DC and T cells
PR8-infected and NA-treated DC were washed, incu-
bated in 10% normal mouse serum for 30 min at 4°C, and
stained with FITC-labeled rat anti-mouse CD103 (2E7),
CD11a (2D7), CD62L (MEL-14), CD32/16 (2.4G2), CD43
(S7), CD43a (1B11), CD40 (HM40-3), ICAM-1 (3E2), B7-2
(GL1), B7-1 (16-10A1), IAb (25-9-3), and Kb (AF6-88.5). All
ntibodies were purchased from Pharmingen (San Di-
go, CA).
To determine the number of T cells that contained
ntracellular cytokines IFN-g and IL-4, splenocytes from
DC-immunized mice were incubated with immunizing
peptide and Golgistop (Pharmingen) for 8 h. Cells were
then stained with FITC-conjugated anti-CD4 or anti-CD8,
fixed and permeabilized, and then incubated with cyto-
kine-specific (or isotype control) biotinylated antibodies
followed by PE-conjugated streptavidin. The reagents
and detailed protocol were obtained from Pharmingen.
To identify antigen-specific CD81 T cells, lymphocytes
from the BAL and MLN of virus-infected C57BL/6 mice
were stained with either PE-conjugated DbPA224 or
DbNP366 tetramers (Belz et al., 2000) at room temperature
for 60 min in PBS containing 0.1% BSA and azide. The
cells were washed once and then incubated with FITC-
labeled anti-CD8 for 30 min at 4°C. After they had been
washed twice, immunofluorescence was analyzed by
flow cytometry using either EPICS ELITE (Coulter) or
FACScan (Becton–Dickinson, San Jose, CA) equipment
and CELLQuest software.
Proliferation assays
To measure alloreactive T cell proliferation, DC (H-2b)
were serially diluted in complete medium and 5 3 102–
5 3 104 cells were mixed with 5 3 105 CD41 or CD81
(H-2d) T cells in quadruplicate wells of a 96-well round-
ottom tissue culture plate (Costar, MA). After 3 days at
7°C, 1 mCi of [3H]thymidine (Dupont, Boston, MA) was
added into each well and the amount of 3H incorporated
easured as previously described (Oh and Eichelberger,
999). Specific antibodies were added in some experi-
ents at 2 mg/ml.
TL assays
Five days after stimulation with allogeneic or peptide-
oaded syngeneic DC, T cells were counted and used as
ffector cells. The cytotoxic activity of allogeneic T cells
as determined using 51Cr-labeled MC57G (IA2DbKb)
arget cells. The cytotoxic activity of peptide-specific T
ells was measured in the same way using 51Cr-labeled
815 (H-2d) target cells that had been incubated for 1 h
3with peptide HA518–528. A mixture of 5 3 10 target cells
and various numbers of effector T cells was incubated
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411NEURAMINIDASE AND CD81 T CELL RESPONSESfor 6 h at 37°C. The 51Cr that was released into the
supernatant was quantitated, and the percentage spe-
cific cytotoxicity was calculated using the formula 100 3
(cpmexperimental 2 cpmspontaneous)/(cpmtotal 2 cpmspontaneous).
ytokine ELISA
Supernatants of cultures were harvested and used in
ytokine-specific ELISA following protocols provided by
harmingen. Cytokine-specific capture and detection an-
ibody pairs, and recombinant cytokines, were pur-
hased from Pharmingen. Immunolon I plates (Dynatech,
hantil, VA) were coated with capture antibodies for 24 h
t 4°C before addition of culture supernatants. The man-
facturer’s protocol was followed for each subsequent
tep. OD405 was measured on a kinetic microplate reader
(Molecule Devices, Palo Alto, CA), and the amount of
each cytokine was calculated from a standard curve
generated from the titration of recombinant cytokine.
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